Results 191 to 200 of about 912,975 (349)

Identification of novel neutralizing determinants for protection against HCV

Hepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein   +12 more
wiley   +1 more source

Evolving epidemiology of hepatitis C virus.

Clinical Microbiology and Infection, 2011
D. Lavanchy
semanticscholar   +1 more source

Serological and molecular detection of hepatitis C virus in Amran governorate, Yemen. [PDF]

BMC Infect Dis
Al-Hadheq AA, Al-Ofairi BA, Abakar AD, Mohammed A, Edrees WH, Al-Shehari WA, Al-Jendy AS, Elsiddig YM, Humaid AA.   +8 more
europepmc   +1 more source

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

British Journal of Clinical Pharmacology, EarlyView.
Aim Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).
Allan Kengo, Juan Eduardo Resendiz‐Galvan, Letisha Najjemba, Henry Mugerwa, Amedeo De Nicolò, Antonio D'Avolio, Shakir Atoyebi, Lubbe Wiesner, Elin M. Svensson, Catriona Waitt, Paolo Denti   +10 more
wiley   +1 more source

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.

Gastroenterology, 2016
J. Pawlotsky
semanticscholar   +1 more source

Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Eleanor G. Dixon, Evita Biraua, Edvards Brencsēns, Vitālijs Pašuks, Vija Riekstina, Anete Šperberga, Marisa D. Muckian, James W. Dear, Liga Kuksa, Derek J. Sloan, Helen R. Stagg   +10 more
wiley   +1 more source

TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk

Hepatology, EarlyView., 2022
The systematic approach in elucidating the gain‐of‐function (GOF) roles of TP53 mutations in early liver carcinogenesis. Unique downstream targets of TP53 L3 mutations were identified from chormatin immunoprecipitation sequencing in HCC cell lines, followed by a series of validation assays to substantiate the exclusive transcriptional regulations ...
Yin Kau Lam, Jianqing Yu, Hao Huang, Xiaofan Ding, Alissa M. Wong, Howard H. Leung, Anthony W. Chan, Kelvin K. Ng, Mingjing Xu, Xin Wang, Nathalie Wong   +10 more
wiley   +1 more source

RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer.

, 1993
C A Siegrist, Bénédicte Durand, P. Emery, Ebenezer David, Patrick Hearing, Bernard Mach, Walter Reith   +6 more
openalex   +1 more source

Determinants of hepatitis C virus treatment completion among Los Angeles County residents. [PDF]

BMC Infect Dis
Hernandez-Tamayo C, Stafylis C, Bhardwaj L, Shah RK, Becerra T, Bruce D, Saini R, Saremi N, Thomas I, Manansala-Tan K, Vij AP, Li A, Sudeep N, Gizamba J, Hosseini B, Navarro S, Ufret-Rivera S, Farias AJ, Klausner JD.   +18 more
europepmc   +1 more source